Could a daily pill boost growth in kids with hypochondroplasia?
NCT ID NCT06873035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called infigratinib in children with hypochondroplasia, a condition that causes short stature. The trial has two parts: first, all children receive the drug to see if it safely increases their growth rate; then, some will switch to a placebo to confirm the effect. Up to 24 children aged 3 to 11 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infigratinib (oral drug)
What this could lead to
If successful, this could provide a treatment option to improve growth in children with hypochondroplasia.
What could go wrong
This is an early-to-mid-stage trial with only 24 participants. The drug may not work as hoped, and side effects could require dose changes or stopping treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOCHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Astrid Lindgren Children's Hospital
Solna, Sweden, 17164, Sweden
-
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants
Toulouse, France, 31059, France
-
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, K1H 8L1, Canada
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Childrens Hospital Colorado
Aurora, Colorado, 80045, United States
-
Haukeland University Hospital
Bergen, Norway, 5021, Norway
-
Hospital Pediátrico de Coimbra
Coimbra, Portugal, 3000-602, Portugal
-
Hospital Vithas San Jose
Vitoria-Gasteiz, Spain, 01008, Spain
-
Hôpital Femme Mère Enfant
Bron, France, 69677, France
-
Hôpital Universitaire Necker-Enfants Malades
Paris, France, 75015, France
-
Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
KK Women's and Children's Hospital
Singapore, Singapore, 229899, Singapore
-
London Health Services Center - Children's Hospital of Western Ontario
London, Ontario, N6C 2R5, Canada
-
Manchester University
Manchester, United Kingdom, M13 9WL, United Kingdom
-
Murdoch Children's Research Institute
Parkville, Victoria, 3052, Australia
-
Paediatric Clinical Research Unit at Osla University Hospital
Oslo, Norway, 0372, Norway
-
Sheffield Children's Hospital
Sheffield, United Kingdom, S10 2TH, United Kingdom
-
UCSF Benioff Children's Hospital
Oakland, California, 94609, United States
-
University of Missouri
Columbia, Missouri, 65201, United States
-
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
Madison, Wisconsin, 53705, United States
-
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States